JP2022550458A5 - - Google Patents
Info
- Publication number
- JP2022550458A5 JP2022550458A5 JP2022520471A JP2022520471A JP2022550458A5 JP 2022550458 A5 JP2022550458 A5 JP 2022550458A5 JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022550458 A5 JP2022550458 A5 JP 2022550458A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- individual
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909113P | 2019-10-01 | 2019-10-01 | |
| US62/909,113 | 2019-10-01 | ||
| PCT/US2020/053642 WO2021067506A1 (en) | 2019-10-01 | 2020-09-30 | Methods of treating conditions related to the s1p1 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550458A JP2022550458A (ja) | 2022-12-01 |
| JP2022550458A5 true JP2022550458A5 (cg-RX-API-DMAC7.html) | 2023-10-10 |
Family
ID=75337529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520471A Pending JP2022550458A (ja) | 2019-10-01 | 2020-09-30 | S1p1受容体に関連する状態を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220347158A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037678A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022550458A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220074913A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119280227A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020360413A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022005999A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156182A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291654A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003982A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202114656A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067506A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023135506A1 (en) | 2022-01-13 | 2023-07-20 | Arena Pharmaceuticals, Inc. | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| EP2528894A1 (en) * | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) * | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| KR20190113955A (ko) * | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
-
2020
- 2020-09-30 JP JP2022520471A patent/JP2022550458A/ja active Pending
- 2020-09-30 US US17/765,619 patent/US20220347158A1/en not_active Abandoned
- 2020-09-30 EP EP20873256.0A patent/EP4037678A4/en not_active Withdrawn
- 2020-09-30 CN CN202411419528.2A patent/CN119280227A/zh active Pending
- 2020-09-30 KR KR1020227014194A patent/KR20220074913A/ko not_active Withdrawn
- 2020-09-30 BR BR112022005999A patent/BR112022005999A2/pt not_active Application Discontinuation
- 2020-09-30 MX MX2022003982A patent/MX2022003982A/es unknown
- 2020-09-30 CA CA3156182A patent/CA3156182A1/en active Pending
- 2020-09-30 CN CN202080076189.6A patent/CN115038438A/zh active Pending
- 2020-09-30 WO PCT/US2020/053642 patent/WO2021067506A1/en not_active Ceased
- 2020-09-30 TW TW109134240A patent/TW202114656A/zh unknown
- 2020-09-30 AU AU2020360413A patent/AU2020360413A1/en not_active Abandoned
-
2022
- 2022-03-23 IL IL291654A patent/IL291654A/en unknown